Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18-90
SponsorPengyuan Liu
About this trial
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
Eligibility criteria
Qualifiers
Histopathologically confirmed diagnosis of PC and clinically confirmed diagnosis of CRPC;
Complete and reliable medical history and medical records;
No other primary tumors except CRPC;
Blood tests, liver function, renal function and electrocardiogram are basically normal;
Disqualifiers
History of malignant tumor other than PC within the past 5 years;
Severe abnormalities in the patient's laboratory indices may jeopardize patient safety or compromise this study;
Accompanied by severe underlying diseases that cannot tolerate this therapy;
With acute diseases, such as acute infection, active bleeding;
Trial design
Treatments tested in this trial
- Immunotherapy
- Targeted therapy
- Hyperthermia
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Pengyuan Liu
Lead sponsor
Zhejiang Hospital
Sponsor institution
Source ClinicalTrials.gov